In CRC, genistein can inhibit colon cancer cell migration by reversing EMT through inhibition of the Notch1/NF-κB/slug/E-cadherin pathway (179), suggesting its potential as an antimetabolite for colon cancer. The gene discussed is NOTCH1; the disease is colonic neoplasm.